Seventy-six patients with advanced breast cancer were entered into the current study. They were randomized to receive either idarubicin (IDA) 45 mg/m2 orally or doxorubicin (DX) 75 mg/m2 intravenously (IV), both drugs being administered every 3 weeks. Among 37 evaluable patients who received DX trea
Chemotherapy versus chemoimmunotherapy in advanced adenocarcinoma of the colon and rectum. A prospective randomized study
✍ Scribed by Frederick Richards II; Hyman B. Muss; M. Robert Cooper; Dougľas R. White; John J. Stuart; Virginia Howard; Paula Barnes; Leonard Rhyne; Charles L. Spurr
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 469 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Background: A prospective, multicenter, randomized, phase iii trial comparing the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide (fac) with a combination of vinorelbine and doxorubicin (na) in the treatment of patients with advanced breast carcinoma w
One-hundred-three patients with extensive non-small-cell lung cancer were entered into a prospective, randomized trial to determine the value of MER as an adjuvant to chemotherapy. Patients were stratified according to histology and performance status. All patients received CCNU, methotrexate, and A